AR054382A1 - Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso - Google Patents

Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso

Info

Publication number
AR054382A1
AR054382A1 ARP060102392A ARP060102392A AR054382A1 AR 054382 A1 AR054382 A1 AR 054382A1 AR P060102392 A ARP060102392 A AR P060102392A AR P060102392 A ARP060102392 A AR P060102392A AR 054382 A1 AR054382 A1 AR 054382A1
Authority
AR
Argentina
Prior art keywords
percent
inhibitor
dry weight
glitazone
weight basis
Prior art date
Application number
ARP060102392A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054382(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR054382A1 publication Critical patent/AR054382A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP060102392A 2005-06-10 2006-06-08 Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso AR054382A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68973905P 2005-06-10 2005-06-10
US69052705P 2005-06-14 2005-06-14
US69081405P 2005-06-15 2005-06-15

Publications (1)

Publication Number Publication Date
AR054382A1 true AR054382A1 (es) 2007-06-20

Family

ID=37198127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102392A AR054382A1 (es) 2005-06-10 2006-06-08 Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso

Country Status (14)

Country Link
US (1) US20080193529A1 (https=)
EP (1) EP1893236A2 (https=)
JP (1) JP2008543767A (https=)
KR (1) KR20080018257A (https=)
AR (1) AR054382A1 (https=)
AU (2) AU2006258013A1 (https=)
BR (1) BRPI0613567A2 (https=)
CA (1) CA2610412A1 (https=)
GT (1) GT200600218A (https=)
MX (1) MX2007015612A (https=)
PE (1) PE20070165A1 (https=)
SA (1) SA06270158B1 (https=)
TW (1) TW200716175A (https=)
WO (1) WO2006135693A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0616694B8 (pt) * 2005-09-29 2021-05-25 Novartis Ag processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ATE488227T1 (de) 2007-02-01 2010-12-15 Takeda Pharmaceutical Feste zubereitung mit alogliptin und pioglitazon
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY31291A1 (es) * 2007-08-16 2009-03-31 Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido
PE20091730A1 (es) * 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AU2014262269B2 (en) * 2008-04-03 2017-02-02 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BRPI1008560B1 (pt) 2009-02-13 2021-08-31 Boehringer Ingelheim International Gmbh Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
EP2459531B1 (en) * 2009-07-31 2019-09-11 KRKA, D.D., Novo Mesto Granulate comprising vildagliptin and process for its preparation
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EA201201509A1 (ru) * 2010-05-05 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические составы, содержащие пиоглитазон и линаглиптин
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
CN102657626B (zh) * 2012-05-23 2013-07-17 重庆康刻尔制药有限公司 一种盐酸吡格列酮药物组合片剂
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
JP5922310B2 (ja) * 2013-07-25 2016-05-24 株式会社三和化学研究所 医薬製剤
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
JP7379189B2 (ja) * 2020-01-31 2023-11-14 沢井製薬株式会社 ビルダグリプチン含有コーティング粒子、ビルダグリプチン含有口腔内崩壊錠、ビルダグリプチン含有コーティング粒子の製造方法及びビルダグリプチン含有口腔内崩壊錠の製造方法
TR202010700A2 (tr) * 2020-07-06 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve en az bi̇r farmasöti̇k olarak kabul edi̇lebi̇li̇r eksi̇pi̇yan i̇çeren bi̇r formülasyon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
CA2424770A1 (en) * 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
US6573287B2 (en) * 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
US20070072810A1 (en) * 2003-10-03 2007-03-29 Takeda Pharmaceutical Company, Limited Agent for treating diabetes
US20090253752A1 (en) * 2004-10-25 2009-10-08 Bryan Burkey Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin

Also Published As

Publication number Publication date
AU2010212516A1 (en) 2010-09-16
KR20080018257A (ko) 2008-02-27
PE20070165A1 (es) 2007-03-09
SA06270158B1 (ar) 2010-10-23
BRPI0613567A2 (pt) 2011-01-18
AU2006258013A1 (en) 2006-12-21
EP1893236A2 (en) 2008-03-05
WO2006135693A2 (en) 2006-12-21
GT200600218A (es) 2007-03-28
TW200716175A (en) 2007-05-01
MX2007015612A (es) 2008-02-25
JP2008543767A (ja) 2008-12-04
US20080193529A1 (en) 2008-08-14
CA2610412A1 (en) 2006-12-21
WO2006135693A3 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
AR054382A1 (es) Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso
AR049000A1 (es) Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida
AR052878A1 (es) Formulacion de compresion directa y proceso
RU2009106681A (ru) Гранулированные фармацевтические композиции
AR084101A2 (es) Comprimido de carga de droga alta y proceso para su preparacion
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
PE20060075A1 (es) Composiciones farmaceuticas de alisciren
PE20040104A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
ES2624231T3 (es) Coadyuvante de formación de comprimidos a base de lactosa y celulosa
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
AR107391A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
PE20180398A1 (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
ES2574836T3 (es) Formulación de liberación prolongada de nevirapina
AR105184A1 (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
RU2015129714A (ru) Композиция в форме таблеток, содержащая гидрохлорид цинакалцета
NZ594669A (en) Oral composition of Vorinostat
AR048970A1 (es) Formulacion farmaceutica solida
AR099137A2 (es) Formulación para compresión directa y proceso
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
TH74669A (th) สูตรและกรรมวิธีการอัดแบบโดยตรง

Legal Events

Date Code Title Description
FB Suspension of granting procedure